Advertisement
Singapore markets close in 28 minutes
  • Straits Times Index

    3,145.81
    -37.80 (-1.19%)
     
  • Nikkei

    38,471.20
    -761.60 (-1.94%)
     
  • Hang Seng

    16,248.97
    -351.49 (-2.12%)
     
  • FTSE 100

    7,847.21
    -118.32 (-1.49%)
     
  • Bitcoin USD

    63,328.46
    -2,966.97 (-4.48%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     
  • Dow

    37,735.11
    -248.13 (-0.65%)
     
  • Nasdaq

    15,885.02
    -290.08 (-1.79%)
     
  • Gold

    2,385.40
    +2.40 (+0.10%)
     
  • Crude Oil

    85.31
    -0.10 (-0.12%)
     
  • 10-Yr Bond

    4.6280
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,536.52
    -6.01 (-0.39%)
     
  • Jakarta Composite Index

    7,174.31
    -112.57 (-1.54%)
     
  • PSE Index

    6,404.97
    -157.46 (-2.40%)
     

Epidiolex Launch Expected to Push Up GW’s Operating Expenses

Epidiolex Launch Expected to Push Up GW’s Operating Expenses

On its fiscal 2018 fourth-quarter earnings conference call, GW Pharmaceuticals (GWPH) projected its operating expenses for the quarter that ends on December 31 to fall to the range of $90 million–$100 million, higher than the $83 million it reported in the previous quarter.